Vδ2 T-cell engagers bivalent for Vδ2-TCR binding provide anti-tumor immunity and support robust Vγ9Vδ2 T-cell expansionLisa A. King(Leiden University Medical Center)Frontiers in OncologyOctober 18, 202410.3389/fonc.2024.1474007Cited by 2SaveCiteExport RISWatch citationsRelated PapersA Bispecific γδ T-cell Engager Targeting EGFR Activates a Potent Vγ9Vδ2 T cell–Mediated Immune Response against EGFR-Expressing Tumors|Cancer Immunology Research|2023|35Leveraging Vγ9Vδ2 T cells against prostate cancer through a VHH-based PSMA-Vδ2 bispecific T cell engager|iScience|2024|5PD-L1 directed bispecific Vδ2-T cell engager combines lysis of PD-L1 expressing tumor cells with PD-1 immune checkpoint inhibition and modulation of the tumor immune microenvironment|Journal for ImmunoTherapy of Cancer|2025|3